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Abstract
Fluorination of fluorophores can substantially enhance their photostability and improve
spectroscopic properties. To facilitate access to fluorinated fluorophores, bis(2,4,5-
trifluorophenyl)methanone was synthesized by treatment of 2,4,5-trifluorobenzaldehyde with a
Grignard reagent derived from 1-bromo-2,4,5-trifluorobenzene, followed by oxidation of the
resulting benzyl alcohol. This hexafluorobenzophenone was subjected to sequential nucleophilic
aromatic substitution reactions, first at one or both of the more reactive 4, 4′ fluorines, and second
by cyclization through substitution of the less reactive 2, 2′ fluorines, using a variety of oxygen,
nitrogen, and sulfur nucleophiles, including hydroxide, methoxide, amines, and sulfide. This
method yields symmetrical and asymmetrical fluorinated benzophenones, xanthones, acridones,
and thioxanthones, and provides scalable access to known and novel precursors to fluorinated
analogues of fluorescein, rhodamine, and other derivatives. Spectroscopic studies revealed that
several of these precursors are highly fluorescent, with tunable absorption and emission spectra,
depending on the substituents. This approach should allow access to a wide variety of novel
fluorinated fluorophores and related compounds.
INTRODUCTION
Substitution of hydrogen with fluorine is extensively employed in medicinal chemistry to
alter the binding of small molecules to biological targets and modulate metabolic
reactivity.1,2 Fluorination can also alter the photophysical properties of compounds.3,4
Fluorination of fluorescein (1, Figure 1) at the 2′- and 7′-positions yields Oregon Green (2),5
a bright fluorophore with decreased phenol pKa (4.8 for 2 versus 6.3–6.86 for 1), improving
fluorescence in acidic aqueous environments, and enhancing photostability. Although a
limited number of fluorinated fluorophores have been reported, modification of other dyes7,8
including Tokyo Green9 (3) to yield Pennsylvania Green (4),10,11 and tetramethylrhodamine
(5) to yield fluorinated rhodamines (e.g. 6)12 can confer beneficial photophysical properties.
However, the synthesis and isolation of single isomers of fluorinated fluorophores such as 5-
carboxy-Oregon Green5 is challenging and costly using existing methods.
To facilitate access to fluorinated fluorophores, we sought to develop a practical method to
synthesize diverse fluorinated xanthone (7), acridone (8), and thioxanthone (9) precursors.
Many of these compounds are biologically active,13–25 some are highly fluorescent,26 and
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the addition of Grignard reagents to protected xanthones has been used to prepare 4-
carboxy-Tokyo Green,9 a fluorescent reporter of kinase activity,27 4-carboxy-Penn Green,10
Tokyo Magenta,28 and other rhodamine and fluorescein analogues.29–32 Methods for
synthesis of derivatives of 7–9 have advanced over the past decade,13,33–41 but only a few
reports27,42–44 describe derivatives with fluorine at the 2 and 7 positions and nitrogen or
oxygen at carbons 3 and 6. Because existing syntheses of fluorinated xanthones and similar
compounds are lengthy and low yielding, relatively little is known about their cognate
photophysical and biological properties.
RESULTS AND DISCUSSION
As shown in Scheme 1, we postulated that repeated SNAr reactions of the novel
benzophenone 10 might allow access to other fluorinated benzophenones (11–12), as well as
xanthones, acridones, and thioxanthones (13), as precursors to more highly conjugated
fluorophores (14).45 The high selectivity observed for the sequential addition of multiple
nucleophiles to cyanuric chloride46 and pentafluoropyridine47 through a similar mechanism
offers precedent for this strategy. To evaluate this hypothesis, we synthesized 10 in a two-
pot process involving magnesium-halogen exchange of inexpensive 1-bromo-2,4,5-
trifluorobenzene (15) followed by addition to 2,4,5-trifluorobenzaldehyde (16) to generate
the alcohol (17) in nearly quantitative yield (Scheme 2). Oxidation with TEMPO free radical
and sodium hypochlorite48 produced benzophenone 10 in excellent overall yield. These
reactions were scalable, and multiple grams of 10 could be produced in a single run.
Using the strategy outlined in Scheme 1, novel fluorinated benzophenone derivatives (18–
29, shown in Figure 2) were prepared from 10 with a variety of oxygen and nitrogen-derived
nucleophiles in good to excellent yields. As summarized in Table 1, heating of 10 in
aqueous KOH/DMSO at 80 °C efficiently substituted both fluorines at the 4, 4′-positions
with hydroxyl groups to afford 18 (Table 1, entry 1). Sodium methoxide added to 10 at room
temperature in nearly quantitative yield to produce 19 (entry 2).
A wide variety of primary and secondary amines generated similar SNAr adducts in good to
excellent yields (Table 1, entries 3 – 12). Piperidine and morpholine exhibited particularly
high reactivity towards 10, and dilution was necessary to prevent formation of tri- and
tetrasubstituted products. As listed in Table 1, either monosubstituted or disubstituted
fluorinated benzophenones derived from ammonia, diethylamine and piperidine (Table 1,
entries 3, 4, 6, 7–10, 11) were obtained in >70% yield by adjusting reaction concentrations
and temperatures, offering additional opportunities for structural diversification.
Symmetrical and asymmetrical xanthones (30–39) were readily accessed by addition of
hydroxide to fluorinated benzophenones using the conditions listed in Table 1. Although
previous routes10,27 to 30, a valuable precursor for preparation of fluorophores such as
Pennsylvania Green, required five to eight steps and achieved only modest overall yields,
heating benzophenone 10 with aqueous NaOH either in a sealed tube at 200 °C for 3 h or at
reflux for 48 h provided 30 in nearly quantitative yield (Table 1, entries 13 and 14). This
latter method was scalable, and multiple grams of 30 could be prepared.
Aminobenzophenones (20–29) were cleanly converted to symmetric and asymetric
xanthones via hydroxide-mediated SNAr reactions with DMSO as a cosolvent (Table 1,
entries 15–23).
Cyclization with amine nucleophiles converted fluorinated benzophenones to fluorinated
acridones (40–48, Figure 3). The conditions for synthesis of 40–48 are summarized in Table
2. Heating of 10 in DMF containing KOH provided N, N-dimethylacridone 41 in 93% yield
(Table 2, entry 2). Decomposition of DMF was responsible for generation of the
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dimethylamine nucleophile. Using the same reaction conditions, acridones 42–45 were
synthesized from benzophenones 25, 21, 27, and 28 in > 90% yield. Dimethoxyacridones
46, 47, and 48, produced by heating 19 with the corresponding amines, required subsequent
treatment with NaH, or heating in higher-boiling dimethylacetamide, for completion.
Attempts to demethylate 46–48 to generate 49–51 with NaSEt or Na2S cleaved only one of
the two methyl groups at 130 °C. Further heating (170 °C) also cleaved the N-linked alkyl
group of 46 and 47. However, reflux with BBr3 in 1,2-dichloroethane provided 49–51 in
high yield (Table 2).
To the best of our knowledge, 2,7-difluorinated thioxanthones have not been previously
reported. To access these compounds, Na2S was employed to synthesize 52–59 (Figure 3) as
summarized in Table 2. By controlling the temperature and concentration of Na2S,
dimethoxybenzophenone 19 was converted into either 52 or 53 (Table 2, entries 13 and 14).
Additionally, diaminobenzophenones 22, 23, 25, 26, 27, and 29 reacted with Na2S at 70 °C
in greater than 85% yield (Table 2, entries 15–20).
Absorbance (18–59) and fluorescence emission spectra (30–59) were acquired on selected
compounds. Values for λmax, molar extinction coefficient (Σ), determined for compounds
with quantum yield (Φ) > 0.2, and Φ relative to diphenylanthracene (Φ = 0.95 in EtOH) and
anthracene (Φ = 0.27 in EtOH) are listed in Table 3. Absorbance and emission spectra of
30–59 are provided in the Supporting Information. Among these compounds, substituents
modulated absorbance by up to 77 nm and emission by up to 71 nm, with Stokes shifts of
>100 nm in some cases. The ability to readily access multigram quantities of these
precursors via iterative SNAr should have broad utility for the synthesis of diverse
fluorinated fluorophores and related molecular probes.
EXPERIMENTAL SECTION
Optical spectroscopy
Quantum yields (Φ) of the highly emissive compounds 30, 31, 35, 36, 38, 40, 42 in ethanol
were quantified by the method of Williams.49 Quantum yields for other compounds were
determined to be < 0.1 by comparison. Diphenylanthracene (Φ = 0.95 in ethanol50) and
anthracene (Φ = 0.27 in ethanol51) were used as standards, and data from these
measurements is provided in the Supporting Information. Molar extinction coefficients (ε) of
30, 31, 35, 36, 38, 40, 42 in ethanol were determined by linear least squares fitting of Beer’s
Law plots of absorbance versus concentration, and data from these measurements is
provided in the Supporting Information.
Synthesis
In addition to specific methods described below, general procedures A–F were used to
access structurally related compounds.
General Procedure A
A mixture of bis(2,4,5-trifluorophenyl)methanone (10, 2.00 g, 6.9 mmol) and the
corresponding amine (73.3 mmol) was heated in a sealed tube. The reaction mixture was
cooled and volatiles were removed in vacuo. If impurities were evident, compounds were
purified by column chromatography (5% EtOAc in hexanes) to provide viscous oils that
typically crystallized when washed with hexanes.
General Procedure B
A mixture of bis(2,4,5-trifluorophenyl)methanone (10, 1.00 g, 3.45 mmol), the
corresponding amine (10.1 mmol), and THF (10.0 mL) were stirred for 12 h at 26 °C. The
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reaction mixture was concentrated in vacuo. If impurities were evident, compounds were
purified by column chromatography (5% EtOAc in hexanes) to give viscous oils that
typically crystallized upon standing.
General Procedure C
A mixture of the corresponding diaminoxanthone (21 – 29, 1.0 mmol), aqueous KOH (10
M, 1.5 mL, 15.0 mmol), and DMSO (1.5 mL) were heated in a sealed tube. After the time
indicated, the reaction mixtures were cooled and transferred to ice water (150 mL). The
resulting precipitate was collected by vacuum filtration and washed with water (3 × 100
mL). If impurities were evident, products were purified by washing with an organic solvent
or by column chromatography.
General Procedure D
The corresponding benzophenone (10, 21, 25, 27, or 28, 1.0 mmol) was dissolved in a
solution of DMF (2.0 mL, 25.9 mmol) and aqueous KOH (10 M, 2.0 mL, 20.0 mmol). This
mixture was heated in a sealed tube and at 150 °C for the time indicated, cooled, and
transferred to ice water (100 mL). The resulting precipitate was filtered, washed with water
(3 × 50 mL) and washed with either diethyl ether or acetone to afford the product.
General Procedure E
The corresponding dimethoxyacridone (46 – 48, 0.10 mmol) was dissolved in 1,2-
dichloroethane (4.0 mL) and treated with BBr3 in CH2Cl2 (0.57 mL of a 0.7 M solution,
0.40 mmol). The reaction mixture was heated to reflux for 12 h, cooled to room temperature,
and quenched with methanol (1.00 mL). The product was concentrated and purified by
column chromatography (0% to 3 % MeOH in CH2Cl2).
General Procedure F
A solution of diaminoxanthone (19, 22, 23, 25 – 27, 29, 1.0 mmol) in DMA (5.0 mL), was
vigorously purged with Ar for 30 min followed by treatment with finely ground Na2S (0.375
g, 5.0 mmol). The resulting yellow-orange slurry was heated to 70 °C for 12 h with stirring.
The hot reaction mixture was poured into ice-cold water (150 mL), and the precipitate was
collected by vacuum filtration. The crude yellow solid was air dried and further purified by
column chromatography or by washing with an organic solvent to give the corresponding
thioxanthone.
Bis(2,4,5-trifluorophenyl)methanone (10)
To a solution of 17 (400 mg, 1.37 mmol) in CH2Cl2 (12 mL) was added KBr (33.2 mg, 0.28
mmol), TEMPO (11.0 mg, 0.07 mmol, 5 mol%), and saturated aqueous NaHCO3. The
biphasic mixture was vigorously stirred and aqueous NaOCl (6.0 mL, 0.7 M) was added.
The resulting bright orange mixture was stirred for 3 h, and the orange color dissipated. The
colorless biphasic layers were separated, the aqueous layer was extracted with CH2Cl2 (2 ×
12 mL), and the combined organic fractions were dried over anhydrous Na2SO4 and
concentrated to give a crude yellow solid. The solid was purified elution through a plug of
silica gel (10% EtOAc in hexanes). The filtrate was concentrated to yield 10 as a colorless
solid (370 mg, 92%). mp 80–81 °C; 1H NMR (CDCl3, 400 MHz) δ 7.57 (qd, J = 8.8, 6.4 Hz,
2H), 6.95 (qd, J = 9.2, 6.4 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 184.7 (s), 156.8 (dd, J =
254.7, 9.8 Hz), 153.3 (ddd, J = 260.0, 14.5, 12.2 Hz), 147.1 (ddd, J = 248.1, 12.7, 3.1 Hz),
123.2 (d, J = 14.9 Hz), 118.8 (d, J = 20.1 Hz), 111.6 – 98.1 (m); IR (thin film) 3073, 1667,
1623, 1509, 1437, 1420, 1333, 1293, 1208, 1138, 889 cm−1; HRMS (ESI) m/z 291.0263 (M
+H+, C13H5F6O requires 291.0245).
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To a solution of 1-bromo-2,4,5-trifluorobenzene (2.34 mL, 20.0 mmol) in THF (30 mL) at
−78 °C was added i-PrMgCl (1.3 M in Et2O, 16.1 mL, 21.0 mmol), dropwise. The resulting
pale yellow solution was stirred at −78 °C for 10 min, was warmed to 4 °C, and was
maintained at 4 °C for 1 h. This solution was cooled again to −78 °C and treated with 2,4,5-
trifluorobenzaldehyde (2.55 mL, 22.0 mmol). This mixture was allowed to slowly warm to
ambient temperature (23 °C). After stirring at room temperature for 3 h, the reaction mixture
was slowly quenched with saturated aqueous NH4Cl solution (20 mL). The resulting phases
were separated, the aqueous fraction was extracted with Et2O (2 × 30 mL), the combined
organic phases were dried over anhydrous Na2SO4, and the solution was concentrated to
give a crude oil that was purified by flash chromatography (5% EtOAc in hexanes) to
provide pure 17 (5.74 g, 99%). mp 81 – 83 °C 1H NMR (CDCl3, 400 MHz) δ 7.27 (qd, J =
10.0, 6.4 Hz, 2H), 6.95 (qd, J = 9.2, 6.4 Hz, 2H), 6.29 (d, J = 3.2 Hz, 1H), 2.46 (d, J =
3.2Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 154.6 (ddd, J = 246.9, 9.3, 2.8 Hz), 151.5 –
148.5 (m), 148.4 – 145.2 (m), 125.4 (d, J = 15.7 Hz), 116.5 – 114.1 (m), 105.8 (dd, J = 27.4,
21.1 Hz), 62.8 (s); IR (thin film) 3364, 1631, 1513, 1430, 1337, 1200, 1147, 1096 cm−1;
HRMS (ESI) m/z 291.0263 (M-H, C13H5F6O requires 291.0245).
Bis(2,5-difluoro-4-hydroxyphenyl)methanone (18)
A mixture of 10 (3.0 g, 10.3 mmol), aqueous KOH (10 M, 10 mL, 100 mmol), and DMSO
(10 mL) was heated to 80 °C for 12 h. This solution was transferred to a mixture of
concentrated aqueous HCl (15 mL) and ice (200 g) to generate a fine precipitate that was
collected by vacuum filtration. This colorless precipitate was washed with cold water (3 ×
100 mL) and dried overnight (16 h) under high vacuum to provide pure 18 (2.71 g, 92%).
mp 170–171 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.40 (brs, 2H), 7.45 (dd, J = 10.8, 7.0
Hz, 2H), 6.83 (dd, J = 11.6, 7.0 Hz, 2H); 13C NMR (126 MHz, DMSO-d6) δ 184.7 (s), 157.1
(d, J = 249.8 Hz), 150.6 (t, J = 13.5 Hz), 147.4 (d, J = 239.6 Hz), 117.4 (dd, J = 15.1, 4.9
Hz), 117.2 (dd, J = 21.5, 3.9 Hz), 104.9 (dd, J = 27.3, 3.0 Hz); IR (film) 3162, 3071, 2964,
1621, 1514, 1303, 1199, 1143, 789 cm−1; HRMS (ESI) m/z 285.0161 (M-H, C13H5F4O3
requires 285.0175).
Bis(2,5-difluoro-4-methoxyphenyl)methanone (19)
A mixture of 10 (2.00 g, 6.8 mmol) and methanol (28 mL) was treated with NaOMe in
methanol (5.4 M, 5.50 mL, 29.6 mmol), dropwise. This mixture was stirred for 12 h, and
water (300 mL) was added. A colorless precipitate was collected by vacuum filtration,
washed with water (2 × 150 mL), and dried under high vacuum to provide of pure 19 (2.11
g, 99%). mp 158–160 °C; 1H NMR (400 MHz, 10% CD3OD in CDCl3) δ 7.47 (dd, J = 10.8,
7.0 Hz, 2H), 6.70 (dd, J = 11.2, 7.0 Hz, 2H); 13C NMR (126 MHz, 10% CD3OD in CDCl3)
δ 185.5 (s), 157.9 (d, J = 252.5 Hz), 152.3 (dd, J = 12.8, 10.6 Hz), 148.4 (dd, J = 244.5, 2.2
Hz), 120.4 – 118.0 (m), 117.1 (dd, J = 21.4, 3.7 Hz), 103.6 – 99.7 (m), 56.6 (s); IR (film)
3066, 2951, 1663, 1621, 1513, 1346, 1145, 794 cm−1; HRMS (ESI) m/z 337.0474 (M+Na+,
C15H10F4O3Na requires 337.0464).
Bis(4-amino-2,5-difluorophenyl)methanone (20)
Bis(2,4,5-trifluorophenyl)methanone (10, 3.00 g, 10.3 mmol) was dissolved in DMSO (10.0
mL) and treated with concentrated aqueous NH4OH (10.0 mL, 145 mmol). This mixture was
stirred at 110 °C for 12 h (sealed tube), followed by addition to ice water (400 mL). A
yellow precipitate was collected by vacuum filtration, washed with water (3 × 150 mL), and
dried under high vacuum for 12 h to provide pure 20 (2.73 g 93%). mp 180–182 °C; 1H
NMR (400 MHz, 10% CD3OD in CDCl3) δ 7.22 (dd, J = 11.2, 7.0 Hz, 2H), 6.37 (dd, J =
11.2, 7.0 Hz, 2H); 13C NMR (10% CD3OD in CDCl3) δ 187.7 (s), 160.1 (d, J = 250.1 Hz),
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148.2 (d, J = 236.3 Hz), 142.6 (dd, J = 15.2, 12.7 Hz), 118.0 (dd, J = 21.0, 3.7 Hz), 117.2 (d,
J = 13.7 Hz), 104.9 – 101.4 (m); IR (film) 3343, 3087, 1627, 1599, 1523, 1459, 1362, 1314,
1371, 750 cm−1; HRMS (ESI) m/z 307.0450 (M+Na+, C13H8F4N2ONa requires 307.0470).
(4-amino-2,5-difluorophenyl)-(2,4,5-trifluorophenyl)methanone (21)
Bis(2,4,5-trifluorophenyl)methanone (10, 1.00 g, 3.43 mmol) in DMSO (2.50 mL) was
treated with concentrated aqueous NH4OH (2.50 mL, 36.3 mmol). This mixture was stirred
at 35 °C for 12 h, diluted with ice-cold water (100 mL), and extracted with EtOAc (3 × 50
mL). The combined organic fractions were dried over anhydrous Na2SO4 and concentrated
in vacuo to give a crude yellow oil that was purified by column chromatography (10% to
20% EtOAc in hexanes) to provide pure 21 (0.738 g, 75%). mp 134–136 °C; 1H NMR (400
MHz, CDCl3) δ 7.39–7.60 (m, 2H), 7.00 (ddd, J = 15.6, 6.0, 3.6 Hz, 1H), 6.43 (dd, J = 11.6,
6.8 Hz, 2H), 4.45 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 184.9 (s), 159.4 (d, J = 252.3 Hz),
155.9 (ddt, J = 252.5, 9.9, 2.5 Hz), 152.2 (ddd, J = 257.0, 14.5, 12.2 Hz), 147.0 (d, J = 239.1
Hz), 148.1 – 145.5 (m), 141.7 (dd, J = 15.2, 12.9 Hz), 127.4 – 123.0 (m), 119.7 – 117.0 (m),
116.8 (dd, J = 21.5, 4.0 Hz), 115.1 (dd, J = 13.4, 5.5 Hz), 106.1 (dd, J = 28.3, 21.1 Hz),
102.2 (dd, J = 28.8, 3.5 Hz); IR (film) 3489, 3343, 3218, 1661, 1593, 1511, 1456, 1425,
1331, 1249, 1144, 900, 787 cm−1; HRMS (ESI) m/z 286.0276 (M-H, C13H5F5NO requires
286.0291).
Bis(4-(dimethylamino)-2,5-difluorophenyl)methanone (22)
Bis(2,4,5-trifluorophenyl)methanone (10, 291 mg, 1.00 mmol) was dissolved in DMF (2.00
mL, 25.9 mmol), treated with aqueous KOH (10 M, 2.00 mL, 20.0 mmol), and stirred at 60
°C for 12 h. This mixture was cooled to room temperature (23 °C), transferred to ice water
(50 mL), extracted with EtOAc (3 × 20 mL), and the combined organic fractions were
washed with water (2 × 30 mL). The organic layer was dried over anhydrous Na2SO4,
concentrated in vacuo, and purified by flash chromatography (5% to 10% EtOAc in
hexanes) to provide pure 22 (265 mg, 78%) as a yellow solid. mp 120–121 °C; 1H NMR
(400 MHz, CDCl3) δ 7.34 (dd, J = 14.1, 7.0 Hz, 2H), 6.39 (dd, J = 12.8, 7.0 Hz, 2H), 3.01
(s, 12H); 13C NMR (126 MHz, CDCl3) δ 185.2 (s), 158.2 (d, J = 249.8 Hz), 148.9 (d, J =
240.7 Hz), 144.7 (s), 120.4 – 116.9 (m), 117.1 – 115.6 (m), 106.9 – 99.3 (m), 42.1 (d, J =
6.1 Hz); IR (film) 2954, 2807, 1619, 1526, 1446, 1359, 1121, 782 cm−1; HRMS (ESI) m/z
341.1259 (M+H+, C17H17F4N2O requires 341.1277).
Bis(4-(diethylamino)-2,5-difluorophenyl)methanone (23)
Using General Procedure A at 90 °C for 12 h, bis(2,4,5-trifluorophenyl)methanone 10 (1.00
g, 3.45 mmol), and diethylamine (7.0 mL, 71.0 mmol) afforded 23 (1.07 g, 85%). mp 60–62
°C; 1H NMR (400 MHz, CDCl3) δ 7.34 (dd, J = 12.4, 5.6 Hz, 2H), 6.54 (dd, J = 12.8, 5.6
Hz, 2H), 4.50 (d, J = 3.6 Hz, 2H), 1.46 (s, 18H); 13C NMR (126 MHz, CDCl3) δ 184.9 (s),
158.4 (d, J = 249.6 Hz), 148.3 (d, J = 239.2 Hz), 142.5 (s), 118.22 (dd, J = 25.9, 5.2 Hz),
116.4 – 115.5 (m), 102.7 (d, J = 28.7 Hz), 46.0 (d, J = 5.7 Hz), 13.6 – 12.5 (m); IR (film)
2976, 2934, 1618, 1523, 1443, 1394, 1356, 1279, 1234, 1192, 1077, 779 cm−1; HRMS (ESI)
m/z 397.1877 (M+H+, C21H25F4N2O requires 397.1903).
(4-(diethylamino)-2,5-difluorophenyl)-(2,4,5-trifluorophenyl)methanone (24)
Using General Procedure A at 26 °C for 12 h, bis(2,4,5-trifluorophenyl)methanone (10, 2.60
g, 6.90 mmol), and diethylamine (1.02 mL, 10.3 mmol), afforded 24 (1.65 g, 70%) after
column chromatography (5% to 10% EtOAc in hexanes). mp 74–78 °C; 1H NMR (400
MHz, CDCl3) δ 7.35–7.50 (m, 2H), 6.96 (ddd, J = 15.7, 6.2, 3.4 Hz, 1H), 6.32 (dd, J = 14.1,
7.2 Hz, 2H), 3.41 (q, J = 6.2 Hz, 2H), 1.23 (t, J = 6.2 Hz, 2H); 13C NMR (126 MHz, CDCl3)
δ 184.3 (s), 162.6 – 156.0 (m), 155.6 (ddt, J = 252.5, 9.9, 2.5 Hz), 149.4 – 146.1 (m), 147.9
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– 145.2 (m),146.6 (d, J = 239.1 Hz), 141.4 (dd, J = 15.2, 12.9 Hz), 127.2 – 122.7 (m), 118.4
(d, J = 4.5 Hz), 116.4 (dd, J = 21.5, 4.0 Hz), 114.9 (dd, J = 13.4, 5.5 Hz), 105.9 (dd, J =
28.4, 21.1 Hz), 103.0 – 99.5 (m), 46.3 (d, J = 6.3 Hz), 13.1 (d, J = 1.8 Hz); IR (film) 3067,
2980, 2938, 1650, 1607, 1528, 1511, 1424, 1392, 1329, 1280, 1131, 1076, 887, 791 cm−1;
HRMS (ESI) m/z 366.0889 (M+Na+, C17H14F5NONa requires 366.0893).
Bis(2,5-difluoro-4-(isopropylamino)phenyl)methanone (25)
Using General Procedure A, 10 (2.0 g), isopropylamine (6.00 mL, 73.3 mmol), and heating
in a sealed tube at 60 °C for 3 h, provided pure 25 (2.32 g, 92%). mp 91– 92 °C; 1H NMR
(400 MHz, CDCl3) δ 7.35 (dd, J = 12.0, 5.2 Hz, 2H), 6.30 (dd, J = 12.4, 5.6 Hz, 2H), 4.32
(d, J = 5.2 Hz, 2H), 3.66 (hept, J = 6.8 Hz, 2H), 1.30 (s, J = 6.4 Hz, 12H); 13C NMR (126
MHz, CDCl3) δ 185.4 (s), 159.2 (d, J = 249.5 Hz), 146.7 (d, J = 235.7 Hz), 140.9 (dd, J =
14.0, 12.2 Hz), 115.7 (dd, J = 21.7, 4.8 Hz), 114.8 – 113.2 (m), 98.4 – 96.9 (m), 44.2 (s),
22.6 (s); IR (film) 3433, 3366, 2972, 2934, 1625, 1607, 1534, 1456, 1368, 1280, 1156, 907,
727 cm−1; HRMS (ESI) m/z 391.1402 (M+Na+, C19H20F4N2ONa requires 391.1409).
Bis(4-(tert-butylamino)-2,5-difluorophenyl)methanone (26)
Using General Procedure A, 10 (500 mg, 1.72 mmol), t-butylamine (7.00 mL, 71.0 mmol),
and heating at 46 °C for 12 h, afforded 26 (560 mg, 82%). mp 135–137 °C; 1H NMR (400
MHz, CDCl3) δ 7.34 (dd, J = 12.4, 5.6 Hz, 2H), 6.54 (dd, J = 12.8, 5.6 Hz, 2H), 4.50 (d, J =
3.6 Hz, 2H), 1.46 (s, 18H); 13C NMR (126 MHz, CDCl3) δ 184.3 (s), 157.5 (d, J = 249.0
Hz), 146.2 (d, J = 235.6 Hz), 139.2 (s), 114.2 (d, J = 4.5 Hz), 113.4 – 112.4 (m), 99.5 – 97.6
(m), 50.3 (s), 28.3 (s); IR (film) 3436, 2979, 1626, 1534, 1462, 1371, 1288, 1211, 796 cm−1;
HRMS (ESI) m/z 397.1877 (M+H+, C21H25F4N2O requires 397.1903).
Bis(2,5-difluoro-4-(piperidin-1-yl)phenyl)methanone (27)
Using General Procedure B, 10 (1.00 g, 3.45 mmol), piperidine (1.0 mL, 10.1 mmol), and
THF (6.00 mL), and a reaction time of 12 h, afforded 27 (1.28 g, 91%). mp 141–143 °C; 1H
NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 13.3, 6.4 Hz, 2H), 6.53 (dd, J = 12.4, 5.5 Hz, 2H),
3.17 (t, J = 5.2 Hz, 8H), 1.72 (p, J = 5.7 Hz, 8H), 1.61 (p, J = 5.4 Hz, 4H); 13C NMR (126
MHz, CDCl3) δ 185.6 (s), 158.0 (d, J = 251.1 Hz), 150.4 (dd, J = 242.6, 1.6 Hz), 145.7 (s),
119.5 – 117.9 (m), 118.3 – 116.5 (m), 105.1 (s), 51.0 (d, J = 5.0 Hz), 25.8 (s), 24.1 (s); IR
(film) 2937, 2854, 2821, 1614, 1508, 1437, 1385, 1255, 1164, 1123, 782 cm−1; HRMS
(ESI) m/z 421.1877 (M+H+, C23H25F4N2O requires 421.1903).
(2,5-difluoro-4-(piperidin-1-yl)phenyl)(2,4,5-trifluorophenyl)methanone (28)
Using General Procedure B, 10 (640 mg, 2.20 mmol), piperidine (0.24 mL, 2.40 mmol),
THF (10 mL), and a reaction time of 3 h, afforded 28 (600 mg, 76%). mp 71–73 °C; 1H
NMR (400 MHz, CDCl3) δ 7.35–7.52 (m, 2H), 6.96 (ddd, J = 15.7, 6.1, 3.5 Hz, 1H), 6.50
(dd, J = 13.1, 7.0 Hz, 1H), 3.24 (t, J = 5.2 Hz, 4H), 1.71 (p, J = 5.4 Hz, 8H), 1.65 (p, J = 5.2
Hz, 4H); 13C NMR (125 MHz, CDCl3) δ 184.8 (s), 159.0 (d, J = 315.0 Hz), 154.2 (dd, J =
163.8, 12.5 Hz), 150.3 (dd, J = 312.5, 12.3 Hz), 149.5 (d, J = 225.3 Hz), 146.9 (dd, J =
325.3, 9.8 Hz), 146.5 – 146.8 (m), 122.2 – 122.7 (m), 118.3 (d, J = 23.7 Hz), 117.4 (dd, J =
31.6, 5.1 Hz), 116.0 – 116.5 (m), 106.1 (dd, J = 35.5, 26.4 Hz), 104.9 (dd, J = 35.3, 5.0 Hz),
50.8 (s), 25.7 (s), 24.1 (s); IR (film) 3070, 2940, 2856, 1665, 1614, 1509, 1438, 1256, 1126,
878, 758 cm−1; HRMS (ESI) m/z 356.1067 (M+H+, C18H15F5NO requires 356.1074).
Bis(2,5-difluoro-4-morpholinophenyl)methanone (29)
Using General Procedure B, 10 (1.00 g, 3.45 mmol), morpholine (0.75 mL, 8.62 mmol),
THF (8 mL), and a reaction time of 12 h, afforded 29 (1.18 g, 81%). mp 189–191 °C; 1H
NMR (400 MHz, CDCl3) δ 7.37 (dd, J = 6.7, 5.6 Hz, 2H), 6.54 (dd, J = 12.0, 5.2 Hz, 2H),
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3.86 (t, J = 4.6 Hz, 8H), 3.21 (t, J = 4.6 Hz, 8H); 13C NMR (125 MHz, CDCl3) δ 185.3 (s),
158.0 (d, J = 314.7 Hz), 150.5 (d, J = 305.0 Hz), 144.7 (d, J = 12.1 Hz), 119.2 – 119.8 (m),
117.7 (d, J = 30.6 Hz), 105.1 (d, J = 34.4 Hz), 66.6 (s), 49.9 (s); IR (film) 2960, 2916, 2861,
1620, 1509, 1267, 1170, 1115, 782 cm−1; HRMS (ESI) m/z 447.1300 (M+Na+,
C21H20F4N2O3Na requires 447.1308).
2,7-Difluoro-3,6-dihydroxy-xanthen-9-one (30)
A mixture of 10 (4.46 g, 15.4 mmol) and aqueous KOH (10 M, 30 mL, 0.300 mol) was
heated to reflux for 48 h. During this time, 10 slowly dissolved to give a bright yellow-
orange solution. This hot solution was poured onto acidic ice (20 mL of 12 M HCl and 200 g
of ice) and was allowed to stand for 3 h. The resulting colorless slurry was filtered via
vacuum and the filtrate was washed with cool water (3 × 100 mL), ethanol (2 × 50 mL), and
dried under high vacuum to yield pure colorless difluoroxanthone 30 (3.91 g, 96%).
Xanthone 30 had spectral properties identical to those previously reported.27
3-amino-2,7-difluoro-6-hydroxy-9H-xanthen-9-one (31)
Using General Procedure C, 21 (1.17 g, 4.07 mmol) and heating at 150 °C for 12 h, afforded
31 (726 mg, 80%). mp 247–250 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 10.9 Hz,
1H), 7.56 (d, J = 11.3 Hz, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.67 (d, J = 7.2 Hz, 1H), 6.55 (s,
2H); 13C NMR (126 MHz, DMSO-d6) δ 172.7 (s), 154.0 (s), 152.8 (s), 151.3 (d, J = 14.8
Hz), 149.2 (d, J = 85.9 Hz), 147.2 (d, J = 83.7 Hz), 144.1 (d, J = 15.9 Hz), 112.8 (d, J = 5.5
Hz), 110.9 (d, J = 19.9 Hz), 109.7 (d, J = 19.8 Hz), 109.0 – 108.2 (m), 104.7 (d, J = 2.5 Hz),
100.1 (d, J = 4.5 Hz); IR (film) 3369, 3221, 2986, 1614, 1481, 1288, 773 cm−1; HRMS
(ESI) m/z 262.0291 (M-H, C13H6F2NO3 requires 262.0316).
3,6-bis(dimethylamino)-2,7-difluoro-9H-xanthen-9-one (32)
Using General Procedure C, 22 (2.00 g, 5.05 mmol), and heating to 150 °C for 12 h,
afforded 32 (1.61 g, 85%). mp 211–213 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.59 (d, J =
14.0 Hz, 2H), 6.76 (d, J = 7.6 Hz, 2H), 3.03 (s, 12H); 13C NMR (126 MHz, DMSO-d6) δ
172.4 (s), 153.2 (s), 150.7 (s), 149.5 – 144.7 (m), 111.4 (d, J = 6.7 Hz), 110.8 (d, J = 23.7
Hz), 103.1 (d, J = 4.1 Hz), 41.8 (d, J = 6.0 Hz); IR (film) 3450, 2922, 2850, 2798, 1615,
15221, 1447, 1371, 1332, 1257, 1132, 777 cm−1; HRMS (ESI) m/z 341.1087 (M+Na+,
C17H16F2N2O2Na requires 341.1078).
3,6-bis(diethylamino)-2,7-difluoro-9H-xanthen-9-one (33)
Using General Procedure C, 23 (1.50 g, 3.78 mmol), and heating at 170 °C for 12 h,
afforded 33 (1.20 g, 85%). mp 108–109 °C; 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 14.4
Hz, 2H), 6.31 (d, J = 7.3 Hz, 2H), 3.42 (q, J = 7.0 Hz, 8H), 1.23 (t, J = 7.0 Hz, 2H); 13C
NMR (126 MHz, CDCl3) δ 173.0 (s), 152.9 (s), 148.9 (d, J = 219.2 Hz), 142.5 (d, J = 10.5
Hz), 111.1(d, J = 24.9 Hz), 110.8 (d, J = 7.1 Hz), 101.5 (s), 45.1 (d, J = 5.9 Hz), 11.9 (d, J =
1.5 Hz); IR (film) 2976, 2934, 1615, 1519, 1457, 1274, 1246, 1071, 773 cm−1; HRMS (ESI)
m/z 375.1857 (M+H+, C21H25F2N2O2 requires 375.1884).
3-(diethylamino)-2,7-difluoro-6-hydroxy-9H-xanthen-9-one (34)
Using General Procedure C, 24 (1.00 g, 2.92 mmol), and heating at 150 °C for 12 h,
afforded 34 (884 mg, 95%). mp 299–300 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.41 (brs,
1 H), 7.71 (d, J = 10.8 Hz, 1H), 7.59 (d, J = 12.8 Hz, 1H), 7.00 (d, J = 7.0 Hz, 1H), 6.80 (d,
J = 7.3 Hz, 1H), 3.43 (q, J = 6.5 Hz, 4H), 1.17 (t, J = 6.5 Hz, 6H); 13C NMR (126 MHz,
DMSO-d6) δ 172.6 (s), 153.6 (s), 152.9 (s), 151.6 (s), 151.5 (s), 149.9 (d, J = 84.3 Hz),
148.0 (d, J = 84.6 Hz), 143.3 (d, J = 10.1 Hz), 112.8 (d, J = 5.4 Hz), 111.8 – 110.31 (m),
110.3 (s), 104.6 (d, J = 2.6 Hz), 102.4 (s), 45.7 (d, J = 5.9 Hz), 12.8 (s); IR (film) 3069,
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2975, 2733, 1618, 1578, 1475, 1398, 1275, 1213, 1080, 775 cm−1; HRMS (ESI) m/z
318.0916 (M-H, C17H14F2NO3 requires 318.0942).
2,7-difluoro-3,6-bis(isopropylamino)-9H-xanthen-9-one (35)
Using General Procedure C, 25 (2.50 g, 6.79 mmol), and heating at 150 °C for 16 h,
afforded 35 (2.15 g, 92%). mp 238–239 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.54 (d, J =
12.0 Hz, 2H), 6.64 (d, J = 7.2 Hz, 2H), 6.45 (dd, J = 2, 8.0 Hz, 2H), 3.76 (hept, J = 6.4 Hz,
2H), 1.22 (d, J = 6.4 Hz, 12H); 13C NMR (126 MHz, DMSO-d6) δ 172.3 (s), 154.2 (s),
147.7 (d, J = 129.2 Hz), 142.0 (s), 141.8 (s), 110.8 – 106.0 (m), 96.9 (d, J = 3.8 Hz), 43.5
(s), 21.7 (s); IR (film) 3435, 2392, 3968, 2837, 1645, 1610, 1531, 1461, 1296, 1016 cm−1;
HRMS (ESI) m/z 347.1592 (M+H+, C19H21F2N2O2 requires 347.1571).
3,6-bis(tert-butylamino)-2,7-difluoro-9H-xanthen-9-one (36)
Using General Procedure C, 26 (1.00 g, 2.52 mmol), and heating at 150 °C for 12 h,
afforded 36 (848 mg, 90%). mp 289–291 °C; 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J =
12.0 Hz, 2H), 6.75 (d, J = 6.7 Hz, 2H), 4.60 (d, J = 4.9 Hz, 2H), 1.48 (s, 18H); 13C NMR
(126 MHz, CDCl3) δ 174.3 (s), 154.1 (s), 148.8 (d, J = 239.0 Hz), 140.8 (d, J = 13.0 Hz),
110.1 (d, J = 6.7 Hz), 109.4 (d, J = 21.7 Hz), 99.1 (d, J = 2.2 Hz), 51.4 (s), 29.2 (s); IR
(film) 3451, 2972, 1623, 1527, 1491, 1294, 1217, 887, 821 cm−1; HRMS (ESI) m/z
375.1897 (M+H+, C21H25F2N2O2 requires 375.1884).
2,7-difluoro-3,6-di(piperidin-1-yl)-9H-xanthen-9-one (37)
Using General Procedure C, 27 (840 mg, 2.00 mmol), and heating to 170 °C for 12 h,
afforded 37 (733 mg, 92%). mp 200–201 °C; 1H NMR (400 MHz, 10% CD3OD in CDCl3)
δ 7.45 (d, J = 13.2 Hz, 2H), 6.58 (d, J = 6.8 Hz, 2H), 2.99 (t, J = 4.8 Hz, 8H), 1.49 (p, J =
4.8 Hz, 8H), 1.41 (hept, J = 4.8 Hz, 4H); 13C NMR (125 MHz, 10% CD3OD in CDCl3) δ
175.2 (s), 153.9 (s), 151.9 (d, J = 252.0 Hz), 147.3 (d, J =10.1 Hz), 113.5 (d, J = 6.3 Hz),
111.0 (d, J = 23.9 Hz), 105.4 (d, J = 3.8 Hz), 51.1 (d, J = 5.0 Hz), 25.6 (s), 24.0 (s); IR
(film) 2931, 1619, 1461, 1234, 1130, 776 cm−1; HRMS (ESI) m/z 421.1714 (M+Na+,
C23H24F2N2O2Na requires 421.1704).
2,7-difluoro-3-hydroxy-6-(piperidin-1-yl)-9H-xanthen-9-one (38)
Using General Procedure C, 28 (710 mg, 2.01 mmol), and heating at 150 °C for 12 h,
afforded 38 (630 mg, 95%). mp 230–231 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.48 (s,
2H), 7.73 (d, J = 10.8 Hz, 1H), 7.64 (d, J = 13.3 Hz, 1H), 7.03 (d, J = 6.9 Hz, 1H), 7.01 (d, J
= 6.9 Hz, 1H), 3.21 (t, J = 5.4 Hz, 1H), 1.65 (p, J = 5.2 Hz, 1H), 1.58 (p, J = 5.4 Hz,
1H); 13C NMR (126 MHz, DMSO-d6) δ 172.9 (s), 152.6 (d, J = 161.3 Hz), 155.0 (d, J =
155.0 Hz), 152.1 (s), 150.1 (s), 149.7 (s), 147.7 (s), 146.5 (d, J = 10.1 Hz), 113.1 – 112.5
(m), 111.0 (d, J = 20.2 Hz), 110.7 (d, J = 23.5 Hz), 105.9 (s), 104.6 (s), 50.5 (d, J = 5.0 Hz),
25.3 (s), 23.6 (s); IR (film) 3126, 2936, 1625, 1587, 1484, 1296, 1090, 832, 778 cm−1;
HRMS (ESI) m/z 330.0925 (M-H, C18H14F2NO3 requires 330.0942).
2,7-difluoro-3,6-dimorpholino-9H-xanthen-9-one (39)
Using General Procedure C, 29 (1.00 g, 2.36 mmol), and heating at 170 °C for 12 h,
afforded 39 (787 mg, 83%). mp 236–237 °C; 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J =
13.0 Hz, 2H), 6.80 (d, J = 6.8 Hz, 2H), 3.90 (t, J = 5.0 Hz, 8H), 3.26 (t, J = 5.0 Hz, 8H); 13C
NMR (125 MHz, CDCl3) δ 13C NMR (126 MHz, CDCl3) δ 174.4 (s), 153.6 (s), 151.9 (d, J
= 245.9 Hz), 146.1 (d, J = 10.6 Hz), 114.9 (d, J = 7.2 Hz), 112.0 (d, J = 23.5 Hz), 105.5 (d, J
= 3.0 Hz), 66.6 (s), 50.1 (d, J = 4.8 Hz); IR (film) 2921, 2863, 1619, 1473, 1259, 1198,
1123, 1030, 900, 777 cm−1; HRMS (ESI) m/z 403.1490 (M+H+, C21H21F2N2O4 requires
403.1469).
Woydziak et al. Page 9














Bis(2,4,5-trifluorophenyl)methanone 10 (291 mg, 1.00 mmol) was dissolved in
isopropylamine (3.00 mL, 36.7 mmol) and transferred to a sealed tube. The reaction was
stirred at 100 °C for 12 h, and all volatiles were removed under reduced pressure. The
residual oil was purified by flash chromatography to yield 40 (170 mg, 45%) as a white
solid. mp 160–162 °C; 1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 12.0 Hz, 2H), 6.56 (d, J =
8.0 Hz, 2H), 5.01 (hept, J = 7.0 Hz, 1H), 4.34 (brs, 2H), 3.75 (hept, J = 5.92 Hz, 2H), 1.75
(d, J = 7.0 Hz, 6H), 1.33 (d, J = 7.0 Hz, 12H); 13C NMR (126 MHz, CDCl3) δ 173.9 (s),
146.5 (d, J = 238.3 Hz), 140.1 (s), 138.9 (d, J = 13.7 Hz), 112.4 (d, J = 5.8 Hz), 109.7 (d, J =
19.5 Hz), 95.4 (s), 50.8 (s), 43.0 (s), 21.6 (s), 20.5 (s); IR (film) 3437, 3304, 2970, 2934,
1622, 1599, 1498, 1281 cm−1; HRMS (ESI) m/z 388.2204 (M+H+, C22H28F2N3O requires
388.2200).
3,6-bis(dimethylamino)-2,7-difluoro-10-methylacridin-9(10H)-one (41)
Using General Procedure D, 10 (291 mg, 1.00 mmol), a reaction time of 6 h, purification by
washing with acetone, and removal of solvent in vacuo, afforded 41 (307 mg, 93%). mp
200–203 °C; 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 14.2 Hz, 2H), 6.51 (d, J = 6.5 Hz,
2H), 3.73 (s, 3H), 3.06 (s, 12H); 13C NMR (126 MHz, DMSO-d6) δ 172.8 (s), 149.3 (d, J =
241.6 Hz), 144.9 (d, J = 10.3 Hz), 140.4 (s), 113.5 (s), 111.3 (d, J = 22.3 Hz), 102.2 (d, J =
3.3 Hz), 42.0 (d, J = 5.5 Hz), 34.2 (s); IR (film) 2916, 1602, 1329, 1267, 750 cm−1; HRMS
(ESI) m/z 332.1548 (M+H+, C18H20F2N3O requires 332.1574).
2,7-difluoro-3,6-bis(isopropylamino)-10-methylacridin-9(10H)-one (42)
Using General Procedure D, 25 (1.70 g, 4.62 mmol), heating to 80 °C for 12 h, and
purification by washing with ether and removal of solvent in vacuo, afforded 42 (1.58 g,
95%) mp 232–233 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 12.2 Hz, 2H), 6.33 (d,
J = 6.8 Hz, 2H), 4.33 (d, J = 4.0 Hz, 2H), 3.73 (hept, J = 6.6 Hz, 2H), 3.69 (s, 3H), 1.31 (d, J
= 6.3 Hz, 2H); 13C NMR (126 MHz, DMSO-d6) δ 172.5 (s), 146.9 (d, J = 244.4 Hz), 141.3
(s), 140.8 (d, J = 13.9 Hz), 110.4 (d, J = 5.1 Hz), 109.3 (d, J = 18.9 Hz), 94.9 (d, J = 3.1 Hz),
43.1 (s), 34.3 (s), 21.9 (s); IR (film) 3405, 3302, 2970, 1623, 1596, 1505, 1284, 1034, 800
cm−1; HRMS (ESI) m/z 360.1866 (M+H+, C20H24F2N3O requires 360.1887).
3-amino-6-(dimethylamino)-2,7-difluoro-10-methylacridin-9(10H)-one (43)
Using General Procedure D, 21 (300 mg, 1.05 mmol), a reaction time of 12 h, and
purification by washing with ether and removal of solvent in vacuo, afforded 43 (295 mg,
93%). mp 263–264 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.75 (d, J = 14.3 Hz, 1H), 7.71 (d,
J = 11.7 Hz, 1H), 6.89 (d, J = 7.4 Hz, 1H), 6.80 (d, J = 7.6 Hz, 1H), 6.24 (s, 2H), 3.75 (s,
3H), 3.03 (s, 6H); 13C NMR (101 MHz, DMSO-d6) δ 173.3 (s), 149.8 (d, J = 200.6 Hz),
147.4 (d, J = 250.7 Hz), 145.1 (d, J = 10.3 Hz), 143.3 (s), 143.1 (s), 141.5 (s), 140.5 (s),
113.9 (d, J = 6.3 Hz), 111.8 (d, J = 22.3 Hz), 110.6 (d, J = 18.6 Hz), 102.5 (d, J = 3.3 Hz),
99.0 (d, J = 3.9 Hz), 42.5 (s), 34.4 (s); IR (film) 3322, 3176, 1619, 1493, 1309, 1256, 1026,
902, 777 cm−1; HRMS (ESI) m/z 304.1260 (M+H+, C16H16F2N3O requires 304.1261).
2,7-difluoro-10-methyl-3,6-di(piperidin-1-yl)acridin-9(10H)-one (44)
Using General Procedure D, 27 (1.50 g, 3.58 mmol), a reaction time of 4 h, and purification
by washing the product with ether and removal of solvent in vacuo, afforded 44 (1.37 g,
93%). mp 243–244 °C; 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 12.1 Hz, 2H), 6.69 (d, J
= 6.9 Hz, 2H), 3.74 (s, 3H), 3.21 (t, J = 5.2 Hz, 8H), 1.79 (p, J = 5.2 Hz, 8H), 1.64 (hept, J =
5.2 Hz, 4H); 13C NMR (126 MHz, CDCl3) δ 174.9 (s), 151.1 (d, J = 245.7 Hz), 146.5 (d, J =
10.4 Hz), 140.3 (s), 115.9 (d, J = 6.7 Hz), 112.6 (d, J = 22.5 Hz), 102.9 (d, J = 2.7 Hz), 51.5
(d, J = 4.5 Hz), 34.2 (s), 26.0 (s), 24.2 (s); IR (film) 2938, 2846, 1624, 1597, 1494, 1274,
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1225, 1145, 783 cm−1; HRMS (ESI) m/z 412.2196 (M+H+, C24H28F2N3O requires
412.2200).
3-(dimethylamino)-2,7-difluoro-10-methyl-6-(piperidin-1-yl)acridin-9(10H)-one (45)
Using General Procedure D, 28 (355 mg, 1.00 mmol), a reaction time of 12 h, and
purification by washing with ether and removal of solvent in vacuo, afforded 45 (338 mg,
91%). mp 227–229 °C; 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 12.6 Hz, 1H), 7.96 (d, J
= 14.2 Hz, 1H), 6.65 (d, J = 6.9 Hz, 1H), 6.43 (d, J = 7.2 Hz, 1H), 3.67 (s, 3H), 3.19 (t, J =
5.2 Hz, 4H), 3.05 (s, 6H), 1.78 (p, J = 5.4 Hz, 4H), 1.65 (p, J = 5.4 Hz, 2H); 13C NMR (126
MHz, DMSO-d6) δ 173.6 (s), 151.3 (d, J = 138.6 Hz), 149.5 (d, J = 127.8 Hz), 146.1 (d, J =
10.4 Hz), 145.5 (d, J = 10.0 Hz), 141.1 (s), 141.0 (s), 115.5 (s), 114.2 (s), 111.9 (d, J = 22.5
Hz), 111.7 (d, J = 22.6 Hz), 104.7 (d, J = 2.6 Hz), 102.4 (d, J = 3.4 Hz), 51.5 (d, J = 4.7 Hz),
42.5 (d, J = 5.8 Hz), 34.7 (s), 26.0 (s), 24.2 (s); IR (film) 2836, 1626, 1601, 1503, 1280,
1011, 895 cm−1; HRMS (ESI) m/z 372.1889 (M+H+, C21H24F2N3O requires 372.1887).
2,7-difluoro-10-isopropyl-3,6-dimethoxyacridin-9(10H)-one (46)
A solution of 19 (100 mg, 0.32 mmol) in isopropylamine (3.00 mL, 36.6 mmol) was heated
to 100 °C in a sealed tube for 12 h. This mixture was cooled and residual isopropylamine
removed in vacuo. The resulting crude yellow oil was dissolved in THF (7.00 mL), treated
with NaH (60%, 77.0 mg, 1.92 mmol), and heated to 60 °C for 12 h. The reaction mixture
was cooled in an ice bath and carefully neutralized with saturated aqueous NaHCO3 (20
mL). Extraction with THF (3 × 20 mL), drying of the combined organic fractions over
anhydrous Na2SO4, and removal of solvent in vacuo provided a crude yellow oil that was
purified by column chromatography (CH2Cl2) to provide dimethoxyacridone 46 (88.4 mg,
83%). mp 158–159 °C; 1H NMR (400 MHz, CDCl3) δ 8.14 (d, J = 11.2 Hz, 2H), 7.04 (d, J
= 6.8 Hz, 2H), 5.09 (p, J = 7.2 Hz, 1H), 4.06 (s, 6H), 1.83 (d, J = 7.2 Hz, 6H); 13C NMR
(126 MHz, CDCl3) δ 175.3 (s), 152.1 (d, J = 12.9 Hz), 148.5 (d, J = 245.9 Hz), 140.2 (s),
117.0 (d, J = 5.4 Hz), 112.8 (d, J = 18.9 Hz), 100.1 (s), 56.4 (s), 52.4 (s), 21.4 (s); IR (film)
2924, 2851, 1736, 1626, 1603, 1488, 1263, 1091, 796 cm−1; HRMS (ESI) m/z 334.1255 (M
+H+, C18H18F2NO3 requires 334.1255).
10-benzyl-2,7-difluoro-3,6-dimethoxyacridin-9(10H)-one (47)
A solution of 19 (1.50 g, 4.78 mmol) in benzylamine (8.00 mL, 73.3 mmol) was heated to
100 °C for 12 h. This mixture was cooled and residual benzylamine removed by vacuum
distillation (36 °C, 1 mm Hg). The resulting crude yellow oil was dissolved in THF (30 mL),
treated with NaH (60%, 574 mg, 14.4 mmol), and heated to 60 °C for 12 h. The reaction
mixture was cooled in an ice bath and carefully neutralized with saturated aqueous NaHCO3
(20 mL). The resulting biphasic mixture was extracted with THF (3 × 20 mL) and the
combined organic fractions were dried over anhydrous Na2SO4 and concentrated to give a
crude yellow oil that was purified by column chromatography (CH2Cl2) to provide
dimethoxyacridone 47 (1.56 g, 86%). mp 205–206 °C; 1H NMR (400 MHz, CDCl3) δ 8.00
(d, J = 11.2 Hz, 2H), 7.45-7.30 (m, 3H), 7.22 (d, J = 6.8 Hz, 2H), 6.93 (d, J = 6.8 Hz, 2H),
5.70 (s, 2H), 4.82 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 174.9 (s), 153.0 (d, J = 13.0 Hz),
148.7 (d, J = 246.0 Hz), 140.1 (s), 135.1 (s), 129.5 (s), 128.22 (s), 125.6 (s), 115.6 (d, J =
5.4 Hz), 112.5 (d, J = 19.1 Hz), 98.5 (s), 56.21 (s), 51.6 (s); IR (film) 2989, 2938, 1607,
1498, 1273, 1042 cm−1; HRMS (ESI) m/z 382.1278 (M+H+, C22H18F2NO3 requires
382.1255).
2,7-difluoro-3,6-dimethoxy-10-phenylacridin-9(10H)-one (48)
A solution of 19 (100 mg, 0.320 mmol) in aniline (2.00 mL, 21.9 mmol) was heated to 130
°C for 12 h in a sealed tube. The reaction mixture was cooled and the residual aniline was
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removed by vacuum distillation (40 °C, 1 mm Hg). The resulting crude yellow oil was
dissolved in DMA (3.5 mL) and heated at 170 °C for 12 h. The reaction mixture was cooled,
diluted with water (30 mL), and extracted with THF (3 × 20 mL). The combined organic
fractions were dried over anhydrous Na2SO4 and concentrated to give a crude yellow oil that
was purified by column chromatography (CH2Cl2) to provide dimethoxyacridone 48 (84.5
mg, 72%). mp 256–257 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.96 (d, J = 11.6 Hz, 2H),
7.74–7.87 (m, 3H), 7.59 (d, J = 7.2 Hz, 2H), 6.17 (d, J = 7.2 Hz, 2H)), 3.62 (s, 6H); 13C
NMR (126 MHz, DMSO-d6) δ 173.5 (s), 151.8 (d, J = 13.1 Hz), 148.0 (d, J = 244.2 Hz),
140.7 (s), 138.0 (s), 131.4 (s), 130.3 (s), 129.6 (s), 113.9 (d, J = 5.1 Hz), 111.0 (d, J = 18.7
Hz), 100.1 (s), 55.8 (s); IR (film) 3057, 2939, 1612, 1580, 1479, 1306, 1256, 1084, 823, 701
cm−1; HRMS (ESI) m/z 368.1098 (M+H+, C21H16F2NO3 requires 368.1098).
2,7-difluoro-3,6-dihydroxy-10-isopropylacridin-9(10H)-one (49)
Using General Procedure E, 46 (20.0 mg, 0.0601 mmol) afforded dihydroxylacridone 49
(15.2 mg, 83%). mp 172–173 °C; 1H NMR (400 MHz, CD3OD) δ 7.95 (d, J = 11.6 Hz, 2H),
7.29 (d, J = 7.2 Hz, 2H), 5.18 (p, J = 7.2 Hz, 2H), 1.75 (d, J = 7.2 Hz, 2H); 13C NMR (126
MHz, CD3OD) δ 177.2 (s), 152.4 (d, J = 15.4 Hz), 149.6 (d, J = 242.1 Hz), 142.1 (s), 116.7
(d, J = 5.1 Hz), 112.8 (d, J = 19.2 Hz), 105.2 (s), 53.6 (s), 20.9 (s); IR (film) 3357, 3075,
2977, 1701, 1627, 1542, 1490, 1448, 1406, 1277, 1199, 889, 770 cm−1; HRMS (ESI) m/z
304.0765 (M-H, C16H12F2NO3 requires 304.0785).
10-benzyl-2,7-difluoro-3,6-dihydroxyacridin-9(10H)-one (50)
Using General Procedure E, 47 (20.0 mg, 0.0526 mmol) afforded dihydroxyacridone 50
(17.0 mg, 91%). mp 247–249 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 11.2 Hz,
2H), 7.25–7.45 (m, 3H), 7.18 (d, J = 7.2 Hz, 2H), 6.97 (d, J = 7.2 Hz, 2H), 5.53 (s, 2H); 13C
NMR (126 MHz, DMSO-d6) δ 173.6 (s), 151.2 (s), 147.8 (d, J = 241.4 Hz), 140.3 (s), 135.6
(s), 129.0 (s), 127.4 (s), 125.7 (s), 113.8 (s), 111.6 (d, J = 18.9 Hz), 102.8 (s), 50.3 (s); IR
(film) 3369, 3050, 3007, 1629, 1574, 1490, 1276, 750 cm−1; HRMS (ESI) m/z 352.0776 (M-
H, C20H12F2NO3 requires 352.0785).
2,7-difluoro-3,6-dihydroxy-10-phenylacridin-9(10H)-one (51)
Using General Procedure E, 48 (20.0 mg, 0.0545 mmol) afforded dihydroxylacridone 51
(14.6 mg, 79%). mp 257–259 °C; 1H NMR (400 MHz, CD3OD) δ 8.10 (d, J = 11.2 Hz, 2H),
7.75–7.90 (m, 3H), 7.49 (d, J = 6.8 Hz, 2H), 6.36 (d, J = 7.2 Hz, 2H); 13C NMR (126 MHz,
CD3OD) δ 174.4 (s), 154.1 (d, J = 15.5 Hz), 150.7 (d, J = 245.7 Hz), 143.3 (s), 140.1 (s),
132.6 (s), 131.6 (s), 130.6 (s), 113.6 (d, J = 6.2 Hz), 112.0 (d, J = 20.4 Hz), 104.8 (d, J = 2.4
Hz); IR (film) 3369, 3064, 2924, 1727, 1624, 1547, 1489, 1395, 1268, 1193, 893 cm−1;
HRMS (ESI) m/z 338.0609 (M-H, C19H10F2NO3 requires 338.0629).
2,7-difluoro-3,6-dimethoxy-9H-thioxanthen-9-one (52)
Using General Procedure F, 19 (3.15 g, 10.0 mmol), 26 °C, and purification by washing with
water (3 × 100 mL), methanol (3 × 50 mL), acetone (3 × 50 mL), and removal of solvent in
vacuo, afforded 52 (2.74 g, 92%). mp >300 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J
= 12.0 Hz, 2H), 7.67 (d, J = 8.0 Hz, 2H), 4.032 (s, 2H); IR (film) 3047, 2967, 1603, 1419,
1346, 1263, 1046, 894, 771 cm−1; HRMS (ESI) m/z 309.0407 (M+H+, C15H11F2O3S
requires 309.0397).
2,7-difluoro-3,6-dihydroxy-9H-thioxanthen-9-one (53)
Using General Procedure F, 19 (1.58 g, 5.00 mmol), heating to 90 °C, and purification by
column chromatography (1% to 3% MeOH in CH2Cl2), afforded 53 (1.04 g, 74%). mp >300
°C; 1H NMR (400 MHz, DMSO-d6) δ 8.03 (d, J = 12.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H),
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3.42 (brs, 2H); 13C NMR (126 MHz, DMSO) δ 175.7 (s), 150.5 (d, J = 243.2 Hz), 150.2 (d,
J = 14.1 Hz), 133.4 (d, J = 1.9 Hz), 120.1 (d, J = 5.0 Hz), 115.3 (d, J = 19.5 Hz), 112.7 (d, J
= 2.7 Hz); IR (film) 3393, 3064, 1617, 1553, 1502, 1413, 1391, 1303, 1287, 1182, 1114, 903
cm−1; HRMS (ESI) m/z 278.9924 (M-H, C13H5F2O3S requires 278.9927).
3,6-bis(dimethylamino)-2,7-difluoro-9H-thioxanthen-9-one (54)
Using General Procedure F, 22 (150 mg, 0.440 mmol), and purification by column
chromatography (10% to 20% EtOAc in hexanes), afforded 54 (134 mg, 91%). mp 218–220
°C; 1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 15.1 Hz, 2H), 6.63 (d, J = 8.0 Hz, 2H), 3.02
(s, 12H); 13C NMR (126 MHz, CDCl3) δ 175.8 (s), 151.4 (d, J = 246.1 Hz), 142.7 (d, J =
10.0 Hz), 132.9 (s), 119.5 (d, J = 6.3 Hz), 114.8 (d, J = 23.5 Hz), 110.0 (d, J = 3.7 Hz), 41.1
(d, J = 6.0 Hz); IR (film) 2907, 2898, 2853, 1682, 1601, 1583, 1354, 1256, 1116, 722 cm−1;
HRMS (ESI) m/z 335.1042 (M+H+, C17H17F2N2OS requires 335.1030).
3,6-bis(diethylamino)-2,7-difluoro-9H-thioxanthen-9-one (55)
Using General Procedure F, 23 (1.10 g, 2.77 mmol), and purification by column
chromatography (10% to 20% EtOAc in hexanes), afforded 55 (973 mg, 90%). mp 145–147
°C; 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 15.6 Hz, 2H), 6.66 (d, J = 8.0 Hz, 2H), 3.40
(q, J = 7.0 Hz, 8H), 1.21 (t, J = 7.0 Hz, 12H); 13C NMR (101 MHz, CDCl3) δ 176.7 (s),
152.1 (d, J = 312.5 Hz), 141.8 (d, J = 9.9 Hz), 134.0 (d, J = 1.5 Hz), 119.7 (s), 116.3 (d, J =
24.3 Hz), 110.6 (s), 46.0 (d, J = 5.8 Hz), 13.0 (d, J = 1.5 Hz); IR (film) 2972, 2931, 2872,
1590, 1504, 1426, 1352, 1264, 1238, 1071, 901, 790 cm−1; HRMS (ESI) m/z 391.1662 (M
+H+, C21H25F2N2OS requires 391.1656).
2,7-difluoro-3,6-bis(isopropylamino)-9H-thioxanthen-9-one (56)
Using General Procedure F, 25 (1.00 g, 2.71 mmol), and purification by column
chromatography (CH2Cl), afforded 56 (834 mg, 85%). mp 164–165 °C; 1H NMR (400
MHz, CDCl3) δ 8.14 (d, J = 12.8 Hz, 2H), 6.59 (d, J = 7.6 Hz, 2H), 4.41 (brs, 2H), 3.74
(hept, J = 6.4 Hz, 2H), 1.33 (d, J = 6.4 Hz, 12H); 13C NMR (126 MHz, CDCl3) 176.9 (s),
150.4 (d, J = 225.5 Hz), 139.3 (d, J = 41.6 Hz), 134.8 (s), 118.2 (s), 113.8 (d, J = 18.9 Hz),
104.9 (s), 44.0 (s), 22.6 (s); IR (film) 3435, 3322, 2969, 1610, 1592, 1515, 1426, 1287,
1326, 1026, 774 cm−1; HRMS (ESI) m/z 363.1338 (M+H+, C19H21F2N2OS requires
363.1343).
3,6-bis(tert-butylamino)-2,7-difluoro-9H-thioxanthen-9-one (57)
Using General Procedure F, 26 (300 mg, 0.762 mmol), and purification by column
chromatography (10% to 20% EtOAc in hexanes), afforded 57 (263 mg, 89%). mp 199–201
°C; 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 13.2 Hz, 2H), 6.33 (d, J = 7.8 Hz, 2H), 4.57
(d, J = 4.6 Hz, 2H), 1.47 (s, 18H), 1.31 (d, J = 6.3 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ
176.9 (s), 150.9 (d, J = 241.0 Hz), 139.2 (d, J = 12.2 Hz), 135.6 – 132.8 (m), 118.0 (d, J =
6.1 Hz), 113.6 (d, J = 21.3 Hz), 106.6 (s), 51.4 (s), 29.3 (s); IR (film) 3437, 2978, 1598,
1514, 1420, 1364, 1202 cm−1; HRMS (ESI) m/z 391.1649 (M+H+, C21H25F2N2OS requires
391.1656).
2,7-difluoro-3,6-di(piperidin-1-yl)-9H-thioxanthen-9-one (58)
Using General Procedure F, 27 (400 mg, 1.00 mmol), and purification by column
chromatography (10% to 20% EtOAc in hexanes), afforded 58 (352 mg, 85%). mp 205–206
°C; 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 14.3 Hz, 2H), 6.87 (d, J = 7.7 Hz, 2H), 3.23
(t, J = 5.2 Hz, 8H), 1.75 (p, J = 5.2 Hz, 8H), 1.63 (hept, J = 5.2 Hz, 4H); 13C NMR (126
MHz, CDCl3) δ 177.1 (s), 153.9 (d, J = 238.1 Hz), 145.1 (d, J = 10.0 Hz), 133.9 (s), 122.0
(d, J = 6.5 Hz), 115.8 (d, J = 23.2 Hz), 113.3 (d, J = 3.0 Hz), 51.2 (d, J = 4.8 Hz), 25.8 (s),
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24.2 (s); IR (film) νmax 2936, 2852, 1624, 1597, 1497, 1420, 1350, 1269, 1252, 1240, 1115,
750 cm−1; HRMS (ESI) m/z 415.1650 (M+H+, C23H25F2N2OS requires 415.1656).
2,7-difluoro-3,6-dimorpholino-9H-thioxanthen-9-one (59)
Using General Procedure F, 29 (213 mg, 0.500 mmol), and purification by column
chromatography (15% to 30% EtOAc in hexanes), afforded 59 (195 mg, 94%). mp 275–276
°C; 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 14.2 Hz, 2H), 6.86 (d, J = 7.6 Hz, 2H), 3.90
(t, J = 4.7 Hz, 8H), 3.26 (t, J = 4.7 Hz, 8H); 13C NMR (126 MHz, CDCl3) δ 176.0 (s), 152.9
(d, J = 258.3 Hz), 143.1 (d, J = 9.9 Hz), 132.8 (d, J = 2.0 Hz), 122.0 (d, J = 6.7 Hz), 115.1
(d, J = 23.1 Hz), 112.1 (d, J = 2.8 Hz), 65.6 (s), 49.1 (d, J = 4.7 Hz); IR (film) 2990, 2923,
2887, 1602, 1499, 1426, 1271, 1122, 1006 cm−1; HRMS (ESI) m/z 441.1056 (M+Na+,
C21H20F2N2O3SNa requires 441.1060).
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Refer to Web version on PubMed Central for supplementary material.
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Structures of fluorinated fluorophores and related compounds.
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Structures of fluorinated benzophenones and xanthones derived from 10.
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Structures of fluorinated acridone and thioxanthone products.
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A general synthesis of fluorinated benzophenones, xanthones, acridones, thioxanthones, and
derivatives involving iterative addition of nucleophiles (Nu:) to bis(2,4,5-
trifluorophenyl)methanone (10).
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Synthesis of bis(2,4,5-trifluorophenyl)methanone (10).
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Table 3
Spectral properties of compounds in ethanol (18–51 and 53–59) or DMSO (52). Values not determined are
indicated by –.
Compd Abs. λmax (nm) ε (M−1 cm−1) Fluor. λmax(nm) Φ
18 306 – – –
19 301 – – –
20 340 – – –
21 335 – – –
22 358 – – –
23 369 – – –
24 361 – – –
25 357 – – –
26 348 – – –
27 354 – – –
28 350 – – –
29 342 – – –
30 369 13300 @ 369 nm 439 0.26
31 366 39200 @ 366 nm 425 0.44
32 378 – 446 < 0.1
33 389 – 452 < 0.1
34 379 – 438 < 0.1
35 370 36200 @ 370 nm 422 0.41
36 368 48600 @ 368 nm 418 0.31
37 369 – 457 < 0.1
38 373 15300 @ 373 nm 445 0.23
39 344 – 448 < 0.1
40 376 36800 @ 376 nm 423 0.32
41 384 – 441 < 0.1
42 377 56700 @ 377 nm 421 0.31
43 369 – 432 < 0.1
44 368 – 455 < 0.1
45 364 – 443 < 0.1
46 383 – 425 < 0.1
47 381 – 416 < 0.1
48 378 – 424 < 0.1
49 379 – 438 < 0.1
50 381 – 431 < 0.1
51 377 – 454 < 0.1
52 316 – 416 < 0.1
53 377 – 465 < 0.1
54 382 – 477 < 0.1
55 393 – 475 < 0.1
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Compd Abs. λmax (nm) ε (M−1 cm−1) Fluor. λmax(nm) Φ
56 377 – 446 < 0.1
57 373 – 432 < 0.1
58 377 – 487 < 0.1
59 361 – 481 < 0.1
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